Implications of mitochondrial redox status and mitophagy in cancer cells' survival
Self-funded PhD students only
School of Pharmacy and Biomedical Sciences
Applications accepted all year round
Applications are invited for a self-funded three-year PhD, to start in October 2019 or February 2020.
The work on this project will:
- Employ a number of cellular and molecular techniques including bioinformatics analysis
- Assess mitochondria-targeting therapeutics
- Investigate mitophagy in the context of oxidative stress
- Identify novel biomarkers to predict cancer outcome
Previous studies have indicated mitochondria as a promising anti-cancer target. Mitochondria are considered a primary intracellular site of reactive oxygen species (ROS) generation. Generally, cancer cells with mitochondrial genetic abnormalities (copy number change and mutations) have escalated ROS levels compared to normal cells. Since high levels of ROS can trigger apoptosis, treating cancer cells with low doses of mitochondria-targeting / ROS-stimulating agents may offer cancer-specific therapy.
Our previous work has shown a correlation between the baseline ROS level and drug sensitivity in several cancer cell lines. A synergistic effect of combining conventional and mitochondria-targeting compounds was also observed with ROS being the key contributor in cell death. The proposed study will continue to delve into mitochondrial redox status and genetic alterations in cancer cells undergoing mitochondria-targeting therapy.
Implications of mitophagy in cancer cells’ survival and the potential link between mitophagy and oxidative stress will also be investigated. A number of cellular and molecular techniques as well as bioinformatics analysis will be required in this project, including cell culture, cytotoxicity assays, ROS assays, PCR, qPCR, DNA sequencing, western blotting, flow cytometry, electron microscopy, fluorescent microscopy, etc.
The student will be co-supervised by Dr An and Prof. Gorecki who have long-standing research experience in the relevant areas. The student will also have access to a skills development program run by the University’s Graduate School. Skills and knowledge obtained from this project will be beneficial for the student to develop a future career in academia or industry.
Bench fees are currently as follows:
Year 1: £18,500
Year 2: £20,000
Year 3: £20,000
PhD full-time and part-time courses are eligible for the UK Government Doctoral Loan (UK and EU students only).
Home/EU full-time students: £4,327 p/a*
Home/EU part-time students: £2,164 p/a*
International full-time students: £15,900 p/a*
International part-time students: £7,950 p/a*
*Fees are subject to annual increase
By Publication Fees 2019/2020
Members of staff: £1,610 p/a*
External candidates: £4,327 p/a*
*Fees are subject to annual increase
You'll need a good first degree from an internationally recognised university (minimum upper second class or equivalent, depending on your chosen course) or a Master’s degree in a relevant subject area. In exceptional cases, we may consider equivalent professional experience and/or Qualifications. English language proficiency at a minimum of IELTS band 6.5 with no component score below 6.0.
- Practical experience in cellular and molecular biology
- An interest in cancer research
How to apply
We’d encourage you to contact Dr Qian An (firstname.lastname@example.org) to discuss your interest before you apply, quoting the project code PHBM4990220 or project title.
When you are ready to apply, you can use our online application form and select ‘Biomedical, Biomolecular and Pharmacy’ as the subject area. Make sure you submit a personal statement, proof of your degrees and grades, details of two referees, proof of your English language proficiency and an up-to-date CV. Our ‘How to Apply’ page offers further guidance on the PhD application process.If you want to be considered for this funded PhD opportunity you must quote project code PHBM4990220 or project title when applying.